The total return over the past 12 months is +170.57% vs. +16.94% for the S&P 500. So far it's up +54.98% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +170.57% | +22.94% | (7.48%) | N/A | N/A | N/A |
| Total Return CAGR | +170.57% | +22.94% | (7.48%) | N/A | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Cullinan Therapeutics, Inc. (CGEM)
| Year | Start price | End price | CGEM Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $10.35 | $16.04 | +54.98% | +14.51% | +40.47% |
| 2025 | $12.18 | $10.35 | (15.02%) | +17.72% | (32.74%) |
| 2024 | $10.19 | $12.18 | +19.53% | +24.89% | (5.36%) |
| 2023 | $10.55 | $10.19 | (3.41%) | +26.19% | (29.60%) |
| 2022 | $15.43 | $10.55 | (31.63%) | (18.17%) | (13.46%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
